OncRef

Clinical Trial: NCT03088878

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Oncternal Therapeutics, Inc
Information Provided By:Oncternal Therapeutics, Inc
Last Update Posted:2025-02-12

Study Overview

Brief Summary

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has been shown to play a role in cell signaling that cause leukemia and lymphoma cells to grow and survive. ROR1 is rarely found on healthy cells.

Official Title

A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Conditions

B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Intervention / Treatment

  • Drug: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
  • Drug: Cirmtuzumab (300mg) plus Ibrutinib
  • Drug: Cirmtuzumab (600 mg) plus ibrutinib
  • Drug: Cirmtuzumab (RDR) plus ibrutinib
  • Drug: Cirmtuzumab plus ibrutinib
  • Drug: Ibrutinib alone

Other Study ID Numbers

  • CIRM-0001 (CIRLL)

Start Date (Actual)

2018-01-03

Primary Completion Date (Actual)

2024-09-25

Study Completion Date (Actual)

2024-09-25

Enrollment (Actual)

95

Study Type

Interventional

Phase

Phase 1, Phase 2